Observational Secondary Data Study describing Treatment with Dapagliflozin among adult Chronic Kidney Disease Patients - OPTIMISE-CKD

Study identifier:D169AR00025

ClinicalTrials.gov identifier:NCT06203704

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

OPTIMISE-CKD CEE: A multinational, observational, secondary data study describing management and treatment with dapagliflozin in routine clinical practice among patients with chronic kidney disease in Central Eastern Europe

Medical condition

Chronic kidney disease (CKD)

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

1090

Study type

Observational

Age

18 Years - 130 Years

Date

Study Start Date: 20 Dec 2023
Estimated Primary Completion Date: 30 Sept 2025
Estimated Study Completion Date: 30 Sept 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria